These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29857274)

  • 41. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles.
    Dutt M; Khuller GK
    J Antimicrob Chemother; 2001 Jun; 47(6):829-35. PubMed ID: 11389115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Biologic treatment of osteoarticular tuberculosis: our experience].
    Cozzolino F; Marasco E; Costa L
    Chir Organi Mov; 1982; 68(4-6):701-5. PubMed ID: 6926884
    [No Abstract]   [Full Text] [Related]  

  • 43. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of the efficacy of drug transdermal delivery by electro-phonophoresis in treating tuberculous lymphadenitis.
    Chen S; Qin M; Han Y; Zhao L; Fu Y; Shang Y; Liu Z; Huang H
    Drug Deliv; 2016 Jun; 23(5):1588-93. PubMed ID: 26669820
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Smartly Engineered PEGylated Di-Block Nanopolymeric Micelles: Duo Delivery of Isoniazid and Rifampicin Against Mycobacterium tuberculosis.
    Rani S; Gothwal A; Khan I; Pachouri PK; Bhaskar N; Gupta UD; Chauhan DS; Gupta U
    AAPS PharmSciTech; 2018 Oct; 19(7):3237-3248. PubMed ID: 30191379
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Isoniazid could be used for antibiotic-loaded bone cement for musculoskeletal tuberculosis: an in vitro study.
    Han CD; Oh T; Cho SN; Yang JH; Park KK
    Clin Orthop Relat Res; 2013 Jul; 471(7):2400-6. PubMed ID: 23504536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis.
    Pandey R; Zahoor A; Sharma S; Khuller GK
    Tuberculosis (Edinb); 2003; 83(6):373-8. PubMed ID: 14623168
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of a novel alginate-polyvinyl alcohol-hydroxyapatite hydrogel for 3D bioprinting bone tissue engineered scaffolds.
    Bendtsen ST; Quinnell SP; Wei M
    J Biomed Mater Res A; 2017 May; 105(5):1457-1468. PubMed ID: 28187519
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mycobactericidal activity of some micro-encapsulated synthetic Host Defense Peptides (HDP) by expediting the permeation of antibiotic: A new paradigm of drug delivery for tuberculosis.
    Sharma A; Vaghasiya K; Ray E; Gupta P; Kumar Singh A; Datta Gupta U; Kumar Verma R
    Int J Pharm; 2019 Mar; 558():231-241. PubMed ID: 30630076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis, characterization, and efficacy of antituberculosis isoniazid zinc aluminum-layered double hydroxide based nanocomposites.
    Saifullah B; El Zowalaty ME; Arulselvan P; Fakurazi S; Webster TJ; Geilich BM; Hussein MZ
    Int J Nanomedicine; 2016; 11():3225-37. PubMed ID: 27486322
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination.
    Pagliotto AD; Caleffi-Ferracioli KR; Lopes MA; Baldin VP; Leite CQ; Pavan FR; Scodro RB; Siqueira VL; Cardoso RF
    J Microbiol Immunol Infect; 2016 Dec; 49(6):980-983. PubMed ID: 26454420
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel biocompatible conducting polyvinyl alcohol (PVA)-polyvinylpyrrolidone (PVP)-hydroxyapatite (HAP) composite scaffolds for probable biological application.
    Chaudhuri B; Mondal B; Ray SK; Sarkar SC
    Colloids Surf B Biointerfaces; 2016 Jul; 143():71-80. PubMed ID: 26998868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of repeated administration of rifampicin and isoniazid on vitamin D metabolism in mice.
    Sheng L; Xue Y; He X; Zhu Y; Li H; Wu Y; Dang R; Tang M; Jiang P
    Steroids; 2015 Dec; 104():203-7. PubMed ID: 26476181
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gold Nanorods as Drug Delivery Vehicles for Rifampicin Greatly Improve the Efficacy of Combating Mycobacterium tuberculosis with Good Biocompatibility with the Host Cells.
    Ali HR; Ali MR; Wu Y; Selim SA; Abdelaal HF; Nasr EA; El-Sayed MA
    Bioconjug Chem; 2016 Oct; 27(10):2486-2492. PubMed ID: 27595304
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment.
    Abate D; Tedla Y; Meressa D; Ameni G
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):946-51. PubMed ID: 25199009
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
    de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
    Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dual antitubercular drug loaded liposomes for macrophage targeting: development, characterisation,
    Shrivastava P; Gautam L; Sharma R; Dube D; Vyas S; Vyas SP
    J Microencapsul; 2021 Mar; 38(2):108-123. PubMed ID: 33267623
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Isoniazid@Fe2 O3 Nanocontainers and Their Antibacterial Effect on Tuberculosis Mycobacteria.
    Leidinger P; Treptow J; Hagens K; Eich J; Zehethofer N; Schwudke D; Oehlmann W; Lünsdorf H; Goldmann O; Schaible UE; Dittmar KE; Feldmann C
    Angew Chem Int Ed Engl; 2015 Oct; 54(43):12597-601. PubMed ID: 26332072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.